Ivax — Merger or Acquisition (August 2005)
7 slides from Ivax's merger presentation, Aug 3, 2005
Slide 1: Annual Shareholders' Meeting August 3, 2005
Annual Shareholders' Meeting August 3, 2005
Slide 2: IVAX / TEVA Agreement
IVAX / TEVA AGREEMENT TEVA to acquire IVAX for an enterprise value of $8.4 billion ($7.4B equity and $1B debt, net of cash) Combination brings together complementary products, pipelines and geographies enhancing growth opportunities Direct presence in more than 50 countries and sales in many more Ap
Slide 3: Strategic Rationale
STRATEGIC RATIONALE Brings together exciting prospects for growth, with proprietary drug offerings in key therapeutic areas including respiratory (IVAX), central nervous system (IVAX and TEVA) and oncology (IVAX and TEVA) Enhances vertical integration between API (active pharmaceutical ingredients)
Slide 4: Complementary Businesses
COMPLEMENTARY BUSINESSES + = 11% 11% 78% 66% 34% 75% 9% 8% 8% Generic $3,749 Innovative $527 API & Other $523 Generic $1,217 Branded $620 Branded $620 Innovative $527 API & Other $523 Generic $4,966 2004 Revenue by Product Type ($ in millions) TEVA - $4,699M IVAX - $1,837M Pro Forma - $6,636M * Figu
Slide 5: A Leading Generic Company
A LEADING GENERIC COMPANY Top 8 Generic Drug Manufacturers (based on 2004 sales) TEVA+IVAX Sandoz+Hexal+Eon Merck KGaA Rationpharm Watson Alpharma Mylan Ranbaxy East 6109 5100 1916 1427 1276 1270 1253 1178 Sales $M * Figures based on information from TEVA presentation
Slide 6: Expanded Therapeutic Proprietary Portfolio
EXPANDED THERAPEUTIC PROPRIETARY PORTFOLIO TEVA MS Copaxone-market leader Oral MS candidates include Copaxone and Laquinimod Other Neurology Agilect/Azilect for Parkinson's Pipeline targeting Alzheimer's Other Autoimmune Lupus Oncology IVAX Respiratory Unique breath-operated inhaler technology, both
Slide 7: 7/29/05
7/29/05